查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649523

全球羟氯喹药物市场预测（2025-2030）

Global Hydroxychloroquine Drugs Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

羟氯喹药品市场预计将从 2025 年的 11.74 亿美元成长到 2030 年的 13.36 亿美元，复合年增长率为 2.62%。

羟氯喹是抗疟疾药，常用于治疗疟疾和类风湿性关节炎、红斑性狼疮等自体免疫疾病。羟氯喹可减轻发炎并调节免疫系统，从而预防自体免疫疾病发作并抑制疟原虫的生长。整体而言，羟氯喹的副作用较小，但偶尔会引起胃肠道刺激和皮疹，长期使用可能会导致视网膜损伤。羟氯喹在新冠疫情期间引起了广泛关注，但其有效性仅在有限的临床试验中得到证实。虽然它仍然是治疗各种慢性病的有效选择，但由于长期使用可能产生副作用，因此必须仔细监测。

推动全球羟氯喹市场的因素

  • 慢性病发病率上升：类风湿性关节炎、红斑性狼疮和疟疾等慢性病发病率上升推动了对羟氯喹的需求。世界卫生组织 (WHO) 已发现 150 多种风湿性或肌肉骨骼疾病可导致不同程度的疼痛和残疾。类风湿性关节炎影响约 0.1% 至 0.3% 的人口，主要影响已开发国家的女性。

疟疾仍然是世界上最受欢迎的疾病之一，羟氯喹可以有效治疗疟疾。根据《2024年世界疟疾报告》，预计2023年全球将有2.63亿人罹患疟疾，较前一年增加。当年死亡人数约59.7万。

地理见解

全球羟氯喹市场分为五个地区：北美、南美、欧洲、中东和非洲、亚太地区。

  • 北美：羟氯喹市场主要受类风湿性关节炎和狼疮等自体免疫疾病高发生率的推动。认识的提高和诊断能力的提高进一步推动了需求。发达的医疗基础设施使人们能够轻鬆获得羟氯喹，同时正在进行的研究正在探索该药物的新用途。
  • 亚太地区：在该地区，羟氯喹的需求受到疟疾高发病率的影响，尤其是在印度、印尼和菲律宾等国家，羟氯奎在疟疾预防和治疗策略中发挥关键作用。

总而言之，由于慢性病和疟疾盛行率的上升，以及各地区医疗保健基础设施意识的不断提高和进步，全球羟氯喹市场预计将成长。

为什么要购买这份报告？

  • 深刻分析：获得深入的市场洞察，涵盖主要和新兴地区，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略与市场占有率分析
  • 各地区（包括细分市场和国家）的收益成长和预测分析
  • 公司概况（策略、产品、财务、主要发展等）

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析

第五章 全球羟氯喹药物市场（依应用）

  • 介绍
  • 类风湿性关节炎
  • 疟疾
  • 其他的

第六章 全球羟氯喹药物市场（依最终用户）

  • 介绍
  • 医院和诊所
  • 门诊手术中心
  • 实验室

第 7 章 全球羟氯喹药物市场（按地区）

  • 世界概况
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 台湾
    • 泰国
    • 印尼
    • 其他亚太地区

第八章 竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第九章 公司简介

  • Novartis AG
  • Sanofi
  • Amneal Pharmaceuticals LLC.
  • Dr. Reddy's Laboratories
  • McKesson Medical-Surgical Inc.
  • Laurus Labs Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Mylan NV
  • Apotex
简介目录
Product Code: KSI061613621

The global hydroxychloroquine drugs market is projected to grow at a CAGR of 2.62%, from US$1.174 billion in 2025 to US$1.336 billion in 2030.

Hydroxychloroquine is an antimalarial medication commonly used to treat malaria, as well as autoimmune diseases such as rheumatoid arthritis and lupus. It works by inhibiting inflammation and regulating the immune system, which helps reduce flare-ups of autoimmune disorders and suppresses the growth of the malaria parasite. Overall, hydroxychloroquine has a favorable side effect profile; however, it can occasionally cause gastrointestinal irritation and skin rashes, with chronic use potentially leading to retinal damage. The drug gained significant attention during the COVID-19 pandemic, although its effectiveness for this purpose has only been supported by a few limited clinical trials. While it remains a valuable option for managing various chronic conditions, careful monitoring is essential due to possible adverse effects associated with long-term use.

Drivers of the Global Hydroxychloroquine Market:

  • Increasing Prevalence of Chronic Conditions: The demand for hydroxychloroquine is being driven by the rising incidence of chronic conditions such as rheumatoid arthritis, lupus, and malaria. The World Health Organization (WHO) identifies over 150 rheumatic or musculoskeletal diseases that can cause varying levels of pain and disability. Rheumatoid arthritis affects approximately 0.1% to 0.3% of the population, predominantly women in developed countries, typically between the ages of 20 and 40.

Malaria remains one of the most widespread diseases globally, treated effectively with hydroxychloroquine. According to the World Malaria Report 2024, there were an estimated 263 million cases of malaria worldwide in 2023, marking an increase from previous years. In that same year, approximately 597,000 deaths were attributed to malaria.

Geographical Insights:

The global hydroxychloroquine market is segmented into five regions: North America, South America, Europe, the Middle East & Africa, and Asia-Pacific.

  • North America: The hydroxychloroquine market in North America is primarily driven by a high prevalence of autoimmune diseases such as rheumatoid arthritis and lupus that require long-term management with this medication. Increased awareness and improved diagnostic capabilities further enhance demand. The advanced healthcare infrastructure ensures easy access to hydroxychloroquine, while ongoing research explores new applications for the drug.
  • Asia-Pacific: In this region, demand for hydroxychloroquine is largely influenced by a high burden of malaria, particularly in countries like India, Indonesia, and the Philippines where it plays a crucial role in malaria prevention and treatment strategies.

In summary, the global hydroxychloroquine market is expected to grow due to rising rates of chronic diseases and malaria, alongside increased awareness and advancements in healthcare infrastructure across various regions.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The global Hydroxychloroquine drugs market is segmented and analyzed as follows:

By Application

  • Rheumatoid Arthritis
  • Malaria
  • Others

By End-User

  • Hospitals and Clinics
  • Ambulatory Surgical Centres
  • Research Labs

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Rest of the Middle East and Africa
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Rest of Asia-Pacific

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL HYDROXYCHLOROQUINE DRUGS MARKET BY APPLICATION

  • 5.1. Introduction
  • 5.2. Rheumatoid Arthritis
  • 5.3. Malaria
  • 5.4. Others

6. GLOBAL HYDROXYCHLOROQUINE DRUGS MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospitals and Clinics
  • 6.3. Ambulatory Surgical Centres
  • 6.4. Research Labs

7. GLOBAL HYDROXYCHLOROQUINE DRUGS MARKET BY GEOGRAPHY

  • 7.1. Global Overview
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Rest of South America
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Rest of Europe
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. United Arab Emirates
    • 7.5.3. Rest of Middle East and Africa
  • 7.6. Asia-Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Indonesia
    • 7.6.8. Rest of Asia-Pacific

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Novartis AG
  • 9.2. Sanofi
  • 9.3. Amneal Pharmaceuticals LLC.
  • 9.4. Dr. Reddy's Laboratories
  • 9.5. McKesson Medical-Surgical Inc.
  • 9.6. Laurus Labs Ltd.
  • 9.7. Lupin Pharmaceuticals, Inc.
  • 9.8. Mylan N.V.
  • 9.9. Apotex